Clinical Trials Logo

Recurrent C. Difficile Infection clinical trials

View clinical trials related to Recurrent C. Difficile Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT05153499 Terminated - Clinical trials for Recurrent C. Difficile Infection

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

PRISM4
Start date: November 15, 2021
Phase: Phase 3
Study type: Interventional

This is a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4). This Phase 3 trial will be conducted in 2 parts: a randomized, double-blind, placebo-controlled trial arm and an optional open-label treatment arm. After completing standard-of-care (SOC) CDI antibiotics for their most recent CDI recurrence, patients who meet all eligibility requirements will be randomized in a 2:1 ratio to receive either CP101 or placebo. Patients will be evaluated for CDI recurrence and safety follow-up through Week 8, the primary endpoint, as well as through Week 24. Patients who qualify may enroll into the optional open label arm if they experience CDI recurrence through week 8.

NCT ID: NCT03298048 Terminated - Clinical trials for Recurrent C. Difficile Infection

Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)

Start date: December 21, 2017
Phase: Phase 2
Study type: Interventional

To establish optimal dosing of lyophilized Fecal microbiota transplantation (FMT) product in the treatment of recurrent C. difficile infection